The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Endocrine Journal

Volumn 58, Issue 11, 2011, Pages 979-987

  Ito, Midori ^a   Abe, Masanori ^a   Okada, Kazuyoshi ^a   Sasaki, Hirokazu ^a   Maruyama, Noriaki ^a,b   Tsuchida, Masaaki ^c   Higuchi, Terumi ^d   Kikuchi, Fumito ^e   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c Tobu Nerima Clinic   (Japan)

^d Department of Nephrology Keiai Hospital   (Japan)

^e Meirikai Chuou General Hospital   (Japan)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitor; Glycemic control; Hemodialysis; Type 2 diabetes; Vildagliptin

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; MITIGLINIDE; VILDAGLIPTIN; VOGLIBOSE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRY WEIGHT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; JAPANESE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT REDUCTION;

EID: 82855178920     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0025     Document Type: Article

References (28)

1. Abe M, Okada K, Soma M (2011) Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 12: 57-69.
2. Yale JF (2005) Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 16: S7-S10.
3. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
4. Sheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12: 648-658.
5. Idris S, Donnelly R (2007) Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab 9: 153-165.
6. Lyseng-Willamson KA (2007) Sitagliptin. Drugs 67: 587-597.
7. Zerilli T, Pyon EY (2007) Sitagliptin phosphate: a DPP-4 inhibitor for the management of type 2 diabetes mellitus. Clin Ther 29: 2614-2634.
8. Henness S, Keam SJ. (2006) Vildagliptin Drugs 66: 1989-2001.
9. Croxtall JD, Keam SJ. (2008) Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 68: 2387-2409.
10. Banerjee M, Younis N, Soran H (2009) Vildagliptin in clinical practice: a review of the literature. Expert Opin Pharmacother 10: 2745-2757.
11. Pratley RE, Kamel-Jauffret S, Galbreath E, Holmes D (2006) Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38: 423-428.
12. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138.
13. Mikhail N (2008) Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig drugs 17: 845-853.
14. Thuren T, Bylers S, Mohideen P, Goodman M (2008) Vildagliptin is safe and well tolerated in patients with mild to moderate renal impairment (Abstract OP 74). Diabetologia 51 (Suppl. 1): S36.
15. Kidney Disease Outcomes Quality Initiative (KDOQI) (2007) Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49: S62-S73.
16. 2007 American Diabetes Association. (2008) Standards of Medical Care in Diabetes-2008. Diabetes Care 31: S12-S54.
17. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y, the Osaka CKD Expert Research Group (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 18: 896-903.
18. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman BI (2008) Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 73: 1062-1068.
19. Abe M, Matsumoto K (2008) Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat Clin Pract Nephrol 4: 482-483.
20. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30: 217-223.
21. Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13: 7-18.
22. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA (2008) Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with sulphonylurea. Diabetes Obes Metab 10: 1047-1056.
23. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K (2010) Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 57: 579-586.
24. Yu L, Lu S, Lin Y, Zeng S (2007) Carboxylglucuronidation of mitiglinide by human UDPglucuronosyltransferases. Biochem Pharmacol 73: 1842-1851.
25. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S (2010) Stringent glycemic control prolongs survival in diabetic patients with end-stage renal disease on hemodialysis. Nephrology 15: 632-638.
26. Barnett A (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60: 1454-1470.
27. Mathieu C, Bollaerts K (2007) Antihyperglycemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 61: 29-37.
28. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S (2007) Management of type 2 diabetes in treatment-naïve elderly patients. Diabetes Care 30: 3017-3022.